Outcomes after autologous SCT in lymphoma patients grouped by weight
Obesity continues to be an increasing global health issue contributing to the complexity of chemotherapy dosing in the field of SCT. Investigation into the optimal dosing weight used to calculate chemotherapy doses in obese patients undergoing SCT is limited and inconclusive. Our single-center, retr...
Gespeichert in:
| Veröffentlicht in: | Bone marrow transplantation (Basingstoke) 2015-05, Vol.50 (5), p.652-657 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 657 |
|---|---|
| container_issue | 5 |
| container_start_page | 652 |
| container_title | Bone marrow transplantation (Basingstoke) |
| container_volume | 50 |
| creator | Lau, J E Weber, C Earl, M Rybicki, L A Carlstrom, K D Wenzell, C M Hill, B T Majhail, N S Kalaycio, M |
| description | Obesity continues to be an increasing global health issue contributing to the complexity of chemotherapy dosing in the field of SCT. Investigation into the optimal dosing weight used to calculate chemotherapy doses in obese patients undergoing SCT is limited and inconclusive. Our single-center, retrospective study compared safety and efficacy outcomes by body mass index (BMI) for 476 adult lymphoma patients who underwent auto-SCT with a myeloablative chemotherapeutic regimen of BU, CY and etoposide dosed using adjusted body weight. Three weight groups categorized based on BMI were defined: normal/underweight ⩽24.9 kg/m
2
, overweight 25–29.9 kg/m
2
and obese ⩾30 kg/m
2
. Severity of mucositis, incidence of secondary malignancy, incidence of bacteremia and median hospital length of stay did not differ among the groups. The median times to absolute neutrophil count and platelet recovery were 10 days (
P
=0.75) and 14 days (
P
=0.17), respectively. Obese patients had a lower 100-day mortality compared with other weight groups, although this did not translate into an OS benefit. OS and disease relapse were similar among the groups. Our study demonstrates that use of adjusted body weight to calculate chemotherapy doses does not negatively have an impact on outcomes in obese patients undergoing auto-SCT with BU, CY and etoposide. |
| doi_str_mv | 10.1038/bmt.2014.327 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_1683354558</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A414693775</galeid><sourcerecordid>A414693775</sourcerecordid><originalsourceid>FETCH-LOGICAL-c624t-a502d00eafdbe70bf76bf02883c754520633ae0eef0d3d29e4b7bc66f3e7f7ca3</originalsourceid><addsrcrecordid>eNqN0k1r3DAQBmBRGppN2lvPxVAoOdRbfcs-hu0nBHJoehayPfIq2JYryYT999WySZOUUIIOAumZkQZehN4SvCaYVZ-aMa0pJnzNqHqBVoQrWQomxUu0wlRWJWOyPkYnMV7jrDgWr9AxFVIKzMkKfb5cUutHiIWxCUJhluQH3_slFj83V4WbimE3zls_mmI2ycGUYtEHv8zQFc2uuAHXb9NrdGTNEOHN7X6Kfn39crX5Xl5cfvuxOb8oW0l5Ko3AtMMYjO0aULixSjYW06pirRJcUCwZM4ABLO5YR2vgjWpaKS0DZVVr2Ck6O_Sdg_-9QEx6dLGFYTAT5B9rIivGcidRPYdiUtVE0kzf_0Ov_RKmPIimklOqGFH1_xSRqlIS05rdq94MoN1kfQqm3T-tzznhsmZKiazWT6i8Ohhd6yewLp8_KvjwoGALZkjb6IclOT_Fx_DjAbbBxxjA6jm40YSdJljv46JzXPQ-LjrHJfN3t0MtzQjdX3yXjwzKA4j5auohPJj6qYZ_ALTAxZo</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1678760293</pqid></control><display><type>article</type><title>Outcomes after autologous SCT in lymphoma patients grouped by weight</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Nature Journals Online</source><source>Alma/SFX Local Collection</source><creator>Lau, J E ; Weber, C ; Earl, M ; Rybicki, L A ; Carlstrom, K D ; Wenzell, C M ; Hill, B T ; Majhail, N S ; Kalaycio, M</creator><creatorcontrib>Lau, J E ; Weber, C ; Earl, M ; Rybicki, L A ; Carlstrom, K D ; Wenzell, C M ; Hill, B T ; Majhail, N S ; Kalaycio, M</creatorcontrib><description>Obesity continues to be an increasing global health issue contributing to the complexity of chemotherapy dosing in the field of SCT. Investigation into the optimal dosing weight used to calculate chemotherapy doses in obese patients undergoing SCT is limited and inconclusive. Our single-center, retrospective study compared safety and efficacy outcomes by body mass index (BMI) for 476 adult lymphoma patients who underwent auto-SCT with a myeloablative chemotherapeutic regimen of BU, CY and etoposide dosed using adjusted body weight. Three weight groups categorized based on BMI were defined: normal/underweight ⩽24.9 kg/m
2
, overweight 25–29.9 kg/m
2
and obese ⩾30 kg/m
2
. Severity of mucositis, incidence of secondary malignancy, incidence of bacteremia and median hospital length of stay did not differ among the groups. The median times to absolute neutrophil count and platelet recovery were 10 days (
P
=0.75) and 14 days (
P
=0.17), respectively. Obese patients had a lower 100-day mortality compared with other weight groups, although this did not translate into an OS benefit. OS and disease relapse were similar among the groups. Our study demonstrates that use of adjusted body weight to calculate chemotherapy doses does not negatively have an impact on outcomes in obese patients undergoing auto-SCT with BU, CY and etoposide.</description><identifier>ISSN: 0268-3369</identifier><identifier>EISSN: 1476-5365</identifier><identifier>DOI: 10.1038/bmt.2014.327</identifier><identifier>PMID: 25665041</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>692/699/1541/1990/291 ; 692/699/1541/1990/291/1621/1915 ; Adult ; Aged ; Analysis ; Autografts ; Bacteremia ; Body mass ; Body mass index ; Body size ; Body Weight ; Bone marrow ; Cancer ; Care and treatment ; Cell Biology ; Chemotherapy ; Diagnosis ; Disease-Free Survival ; Dosage ; Etoposide ; Female ; Global health ; Hematology ; Humans ; Internal Medicine ; Leukocytes (neutrophilic) ; Lymphoma ; Lymphoma - mortality ; Lymphoma - therapy ; Lymphomas ; Male ; Malignancy ; Mathematical analysis ; Medicine ; Medicine & Public Health ; Middle Aged ; Mucositis ; Myeloablative Agonists - administration & dosage ; Obesity ; original-article ; Overweight ; Patients ; Pharmacokinetics ; Public Health ; Retrospective Studies ; Stem Cell Transplantation ; Stem Cells ; Survival Rate ; Transplantation Conditioning - methods ; Underweight</subject><ispartof>Bone marrow transplantation (Basingstoke), 2015-05, Vol.50 (5), p.652-657</ispartof><rights>Macmillan Publishers Limited 2015</rights><rights>COPYRIGHT 2015 Nature Publishing Group</rights><rights>Copyright Nature Publishing Group May 2015</rights><rights>Macmillan Publishers Limited 2015.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c624t-a502d00eafdbe70bf76bf02883c754520633ae0eef0d3d29e4b7bc66f3e7f7ca3</citedby><cites>FETCH-LOGICAL-c624t-a502d00eafdbe70bf76bf02883c754520633ae0eef0d3d29e4b7bc66f3e7f7ca3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,781,785,27928,27929</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25665041$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lau, J E</creatorcontrib><creatorcontrib>Weber, C</creatorcontrib><creatorcontrib>Earl, M</creatorcontrib><creatorcontrib>Rybicki, L A</creatorcontrib><creatorcontrib>Carlstrom, K D</creatorcontrib><creatorcontrib>Wenzell, C M</creatorcontrib><creatorcontrib>Hill, B T</creatorcontrib><creatorcontrib>Majhail, N S</creatorcontrib><creatorcontrib>Kalaycio, M</creatorcontrib><title>Outcomes after autologous SCT in lymphoma patients grouped by weight</title><title>Bone marrow transplantation (Basingstoke)</title><addtitle>Bone Marrow Transplant</addtitle><addtitle>Bone Marrow Transplant</addtitle><description>Obesity continues to be an increasing global health issue contributing to the complexity of chemotherapy dosing in the field of SCT. Investigation into the optimal dosing weight used to calculate chemotherapy doses in obese patients undergoing SCT is limited and inconclusive. Our single-center, retrospective study compared safety and efficacy outcomes by body mass index (BMI) for 476 adult lymphoma patients who underwent auto-SCT with a myeloablative chemotherapeutic regimen of BU, CY and etoposide dosed using adjusted body weight. Three weight groups categorized based on BMI were defined: normal/underweight ⩽24.9 kg/m
2
, overweight 25–29.9 kg/m
2
and obese ⩾30 kg/m
2
. Severity of mucositis, incidence of secondary malignancy, incidence of bacteremia and median hospital length of stay did not differ among the groups. The median times to absolute neutrophil count and platelet recovery were 10 days (
P
=0.75) and 14 days (
P
=0.17), respectively. Obese patients had a lower 100-day mortality compared with other weight groups, although this did not translate into an OS benefit. OS and disease relapse were similar among the groups. Our study demonstrates that use of adjusted body weight to calculate chemotherapy doses does not negatively have an impact on outcomes in obese patients undergoing auto-SCT with BU, CY and etoposide.</description><subject>692/699/1541/1990/291</subject><subject>692/699/1541/1990/291/1621/1915</subject><subject>Adult</subject><subject>Aged</subject><subject>Analysis</subject><subject>Autografts</subject><subject>Bacteremia</subject><subject>Body mass</subject><subject>Body mass index</subject><subject>Body size</subject><subject>Body Weight</subject><subject>Bone marrow</subject><subject>Cancer</subject><subject>Care and treatment</subject><subject>Cell Biology</subject><subject>Chemotherapy</subject><subject>Diagnosis</subject><subject>Disease-Free Survival</subject><subject>Dosage</subject><subject>Etoposide</subject><subject>Female</subject><subject>Global health</subject><subject>Hematology</subject><subject>Humans</subject><subject>Internal Medicine</subject><subject>Leukocytes (neutrophilic)</subject><subject>Lymphoma</subject><subject>Lymphoma - mortality</subject><subject>Lymphoma - therapy</subject><subject>Lymphomas</subject><subject>Male</subject><subject>Malignancy</subject><subject>Mathematical analysis</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Middle Aged</subject><subject>Mucositis</subject><subject>Myeloablative Agonists - administration & dosage</subject><subject>Obesity</subject><subject>original-article</subject><subject>Overweight</subject><subject>Patients</subject><subject>Pharmacokinetics</subject><subject>Public Health</subject><subject>Retrospective Studies</subject><subject>Stem Cell Transplantation</subject><subject>Stem Cells</subject><subject>Survival Rate</subject><subject>Transplantation Conditioning - methods</subject><subject>Underweight</subject><issn>0268-3369</issn><issn>1476-5365</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNqN0k1r3DAQBmBRGppN2lvPxVAoOdRbfcs-hu0nBHJoehayPfIq2JYryYT999WySZOUUIIOAumZkQZehN4SvCaYVZ-aMa0pJnzNqHqBVoQrWQomxUu0wlRWJWOyPkYnMV7jrDgWr9AxFVIKzMkKfb5cUutHiIWxCUJhluQH3_slFj83V4WbimE3zls_mmI2ycGUYtEHv8zQFc2uuAHXb9NrdGTNEOHN7X6Kfn39crX5Xl5cfvuxOb8oW0l5Ko3AtMMYjO0aULixSjYW06pirRJcUCwZM4ABLO5YR2vgjWpaKS0DZVVr2Ck6O_Sdg_-9QEx6dLGFYTAT5B9rIivGcidRPYdiUtVE0kzf_0Ov_RKmPIimklOqGFH1_xSRqlIS05rdq94MoN1kfQqm3T-tzznhsmZKiazWT6i8Ohhd6yewLp8_KvjwoGALZkjb6IclOT_Fx_DjAbbBxxjA6jm40YSdJljv46JzXPQ-LjrHJfN3t0MtzQjdX3yXjwzKA4j5auohPJj6qYZ_ALTAxZo</recordid><startdate>20150501</startdate><enddate>20150501</enddate><creator>Lau, J E</creator><creator>Weber, C</creator><creator>Earl, M</creator><creator>Rybicki, L A</creator><creator>Carlstrom, K D</creator><creator>Wenzell, C M</creator><creator>Hill, B T</creator><creator>Majhail, N S</creator><creator>Kalaycio, M</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QO</scope><scope>7QP</scope><scope>7T5</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FD</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20150501</creationdate><title>Outcomes after autologous SCT in lymphoma patients grouped by weight</title><author>Lau, J E ; Weber, C ; Earl, M ; Rybicki, L A ; Carlstrom, K D ; Wenzell, C M ; Hill, B T ; Majhail, N S ; Kalaycio, M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c624t-a502d00eafdbe70bf76bf02883c754520633ae0eef0d3d29e4b7bc66f3e7f7ca3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>692/699/1541/1990/291</topic><topic>692/699/1541/1990/291/1621/1915</topic><topic>Adult</topic><topic>Aged</topic><topic>Analysis</topic><topic>Autografts</topic><topic>Bacteremia</topic><topic>Body mass</topic><topic>Body mass index</topic><topic>Body size</topic><topic>Body Weight</topic><topic>Bone marrow</topic><topic>Cancer</topic><topic>Care and treatment</topic><topic>Cell Biology</topic><topic>Chemotherapy</topic><topic>Diagnosis</topic><topic>Disease-Free Survival</topic><topic>Dosage</topic><topic>Etoposide</topic><topic>Female</topic><topic>Global health</topic><topic>Hematology</topic><topic>Humans</topic><topic>Internal Medicine</topic><topic>Leukocytes (neutrophilic)</topic><topic>Lymphoma</topic><topic>Lymphoma - mortality</topic><topic>Lymphoma - therapy</topic><topic>Lymphomas</topic><topic>Male</topic><topic>Malignancy</topic><topic>Mathematical analysis</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Middle Aged</topic><topic>Mucositis</topic><topic>Myeloablative Agonists - administration & dosage</topic><topic>Obesity</topic><topic>original-article</topic><topic>Overweight</topic><topic>Patients</topic><topic>Pharmacokinetics</topic><topic>Public Health</topic><topic>Retrospective Studies</topic><topic>Stem Cell Transplantation</topic><topic>Stem Cells</topic><topic>Survival Rate</topic><topic>Transplantation Conditioning - methods</topic><topic>Underweight</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lau, J E</creatorcontrib><creatorcontrib>Weber, C</creatorcontrib><creatorcontrib>Earl, M</creatorcontrib><creatorcontrib>Rybicki, L A</creatorcontrib><creatorcontrib>Carlstrom, K D</creatorcontrib><creatorcontrib>Wenzell, C M</creatorcontrib><creatorcontrib>Hill, B T</creatorcontrib><creatorcontrib>Majhail, N S</creatorcontrib><creatorcontrib>Kalaycio, M</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Biotechnology Research Abstracts</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Bone marrow transplantation (Basingstoke)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lau, J E</au><au>Weber, C</au><au>Earl, M</au><au>Rybicki, L A</au><au>Carlstrom, K D</au><au>Wenzell, C M</au><au>Hill, B T</au><au>Majhail, N S</au><au>Kalaycio, M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Outcomes after autologous SCT in lymphoma patients grouped by weight</atitle><jtitle>Bone marrow transplantation (Basingstoke)</jtitle><stitle>Bone Marrow Transplant</stitle><addtitle>Bone Marrow Transplant</addtitle><date>2015-05-01</date><risdate>2015</risdate><volume>50</volume><issue>5</issue><spage>652</spage><epage>657</epage><pages>652-657</pages><issn>0268-3369</issn><eissn>1476-5365</eissn><abstract>Obesity continues to be an increasing global health issue contributing to the complexity of chemotherapy dosing in the field of SCT. Investigation into the optimal dosing weight used to calculate chemotherapy doses in obese patients undergoing SCT is limited and inconclusive. Our single-center, retrospective study compared safety and efficacy outcomes by body mass index (BMI) for 476 adult lymphoma patients who underwent auto-SCT with a myeloablative chemotherapeutic regimen of BU, CY and etoposide dosed using adjusted body weight. Three weight groups categorized based on BMI were defined: normal/underweight ⩽24.9 kg/m
2
, overweight 25–29.9 kg/m
2
and obese ⩾30 kg/m
2
. Severity of mucositis, incidence of secondary malignancy, incidence of bacteremia and median hospital length of stay did not differ among the groups. The median times to absolute neutrophil count and platelet recovery were 10 days (
P
=0.75) and 14 days (
P
=0.17), respectively. Obese patients had a lower 100-day mortality compared with other weight groups, although this did not translate into an OS benefit. OS and disease relapse were similar among the groups. Our study demonstrates that use of adjusted body weight to calculate chemotherapy doses does not negatively have an impact on outcomes in obese patients undergoing auto-SCT with BU, CY and etoposide.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>25665041</pmid><doi>10.1038/bmt.2014.327</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0268-3369 |
| ispartof | Bone marrow transplantation (Basingstoke), 2015-05, Vol.50 (5), p.652-657 |
| issn | 0268-3369 1476-5365 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1683354558 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Nature Journals Online; Alma/SFX Local Collection |
| subjects | 692/699/1541/1990/291 692/699/1541/1990/291/1621/1915 Adult Aged Analysis Autografts Bacteremia Body mass Body mass index Body size Body Weight Bone marrow Cancer Care and treatment Cell Biology Chemotherapy Diagnosis Disease-Free Survival Dosage Etoposide Female Global health Hematology Humans Internal Medicine Leukocytes (neutrophilic) Lymphoma Lymphoma - mortality Lymphoma - therapy Lymphomas Male Malignancy Mathematical analysis Medicine Medicine & Public Health Middle Aged Mucositis Myeloablative Agonists - administration & dosage Obesity original-article Overweight Patients Pharmacokinetics Public Health Retrospective Studies Stem Cell Transplantation Stem Cells Survival Rate Transplantation Conditioning - methods Underweight |
| title | Outcomes after autologous SCT in lymphoma patients grouped by weight |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-16T17%3A50%3A15IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Outcomes%20after%20autologous%20SCT%20in%20lymphoma%20patients%20grouped%20by%20weight&rft.jtitle=Bone%20marrow%20transplantation%20(Basingstoke)&rft.au=Lau,%20J%20E&rft.date=2015-05-01&rft.volume=50&rft.issue=5&rft.spage=652&rft.epage=657&rft.pages=652-657&rft.issn=0268-3369&rft.eissn=1476-5365&rft_id=info:doi/10.1038/bmt.2014.327&rft_dat=%3Cgale_proqu%3EA414693775%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1678760293&rft_id=info:pmid/25665041&rft_galeid=A414693775&rfr_iscdi=true |